Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Turcot syndrome 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 10Carboplatin 6Bevacizumab 5liposomal doxorubicin 4Topotecan 3Cyclophosphamide 3pembrolizumab 2oregovomab 2olaparib 2niraparib 2fludarabine 2Nivolumab 2Drug Therapy 2trastuzumab deruxtecan 1rucaparib 1ribociclib 1palbociclib 1mirvetuximab soravtansine 1isoquercitrin 1irinotecan sucrosofate 1fludarabine phosphate 1denileukin diftitox 1anlotinib 1Tinzaparin 1Saline Solution 1Propranolol 1Preoperative Exercise 1Platinum 1Palliative Care 1Neoadjuvant Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × denileukin diftitox × 90 days × Clear all
NCT05200559 2026-05-29

T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors

University of Pittsburgh

Phase 1/2 Active not recruiting
25 enrolled
Gynecologic

Turcot syndrome, Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡